Valuation: Pelthos Therapeutics Inc.

Market Cap 41.27M 36.87M 33.87M 30.76M 57.76M 3.91B 59.22M 404M 163M 2.06B 155M 152M 6.54B P/E 2026 *
-0.6x
P/E 2027 * -2.86x
Enterprise Value 41.27M 36.87M 33.87M 30.76M 57.76M 3.91B 59.22M 404M 163M 2.06B 155M 152M 6.54B EV / Sales 2026 *
0.66x
EV / Sales 2027 * 0.38x
Free-Float
48.64%
Yield 2026 *
-
Yield 2027 * -
1 day-6.42%
1 week-25.66%
Current month+14.68%
1 month-47.67%
3 months-59.84%
6 months-56.88%
Current year-65.23%
1 week 9.02
Extreme 9.02
20.5
1 month 9.02
Extreme 9.02
22.95
Current year 9.02
Extreme 9.02
30.99
1 year 9.02
Extreme 9.02
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap. Importance
2/10/26 Sell

Director

-558 0.0161%
2/10/26 Sell

Chairman

-797 0.0229%
2/10/26 Sell

Director

-786 0.0226%
Change 5-day change 1-year change 3-year change Capi.($)
-6.42%-25.66%-68.49% - 41.27M
-0.11%+9.94%+57.20%+148.21% 1,255B
-1.62%-0.95%+42.90%+75.88% 641B
-0.98%-0.14%+34.93%+102.23% 505B
-1.56%-2.01%+50.67%+64.81% 381B
-2.49%+2.01%+75.38%+39.94% 357B
-0.02%+2.11%+32.16%+57.79% 303B
-0.72%+7.32%+11.29%+33.98% 286B
-0.90%+2.97%+55.67%+70.93% 249B
-1.68%+5.27%+37.21%+105.26% 208B
Average -1.65%+0.09%+32.89%+77.67% 418.53B
Weighted average by Cap. -0.94%+3.90%+47.24%+93.67%

Financials

2026 *2027 *
Net sales 62.36M 55.71M 51.17M 46.48M 87.28M 5.91B 89.47M 611M 246M 3.12B 234M 229M 9.88B 108M 96.84M 88.95M 80.79M 152M 10.27B 156M 1.06B 427M 5.42B 407M 398M 17.18B
Net income -65.56M -58.57M -53.8M -48.86M -91.76M -6.21B -94.07M -642M -258M -3.28B -246M -241M -10.39B -30.25M -27.02M -24.82M -22.55M -42.34M -2.87B -43.4M -296M -119M -1.51B -114M -111M -4.79B
Net Debt - -
Projected Income Statement - Annual - Pelthos Therapeutics Inc.
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
03/11/26 US$10.78 -6.42% 41,153
02/11/26 US$11.52 +22.55% 177,542
30/10/26 US$9.400 -43.17% 242,032
29/10/26 US$16.54 +5.08% 14,741
28/10/26 US$15.74 +8.55% 49,702
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Pelthos Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.78USD
Average target price
49.57USD
Spread / Average Target
+359.85%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pelthos Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. PTHS Stock